Koyfin Home > Directory > Health Care > Revance Therapeutics > Net Income

Revance Therapeutics Net Income Chart (RVNC)

Revance Therapeutics annual/quarterly Net Income from 2012 to 2020. Net income is calculated as sales less cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes and other expenses. This number appears on a company's income statement and is an important measure of how profitable the company is.
  • Revance Therapeutics Net Income for the quarter ending June 06, 2020 was $-61m a 31.66% decrease of -19m year over year
  • Revance Therapeutics Net Income for the last 12 months ending June 06, 2020 was $-209m a 26.06% decrease of -55m year over year
  • Revance Therapeutics Annual Net Income for 2019 was $-159m a 10.58% decrease of -17m from 2018
  • Revance Therapeutics Annual Net Income for 2018 was $-143m a 15.42% decrease of -22m from 2017
  • Revance Therapeutics Annual Net Income for 2017 was $-121m a 25.97% decrease of -31m from 2016
Other Income Statement Metrics:
  • Revance Therapeutics EBITDA for the quarter ending December 12, 2018 was $-38m a 7.02% decrease of -3m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Net Income Data

06/2020$-61m
03/2020$-62m
12/2019$-45m
09/2019$-41m
06/2019$-37m
03/2019$-35m
12/2018$-41m
09/2018$-33m
06/2018$-34m
03/2018$-35m

Annual RVNC Net Income Data

2019$-159m
2018$-143m
2017$-121m
2016$-89m
2015$-73m
2014$-63m
2013$-52m
2012$-58m
2011$-45m